HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Angelini finds Catalyst for its US growth ambitions with $4.1B buyout

With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion.

By FiercePharma · May 8, 2026 · via FiercePharma
Angelini finds Catalyst for its US growth ambitions with $4.1B buyout

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
dealsformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics
DealsFierceBiotech ↗
Roche shells out up to $1B for PathAI in move to boost artificial intelligence-powered diagnostics
Roche is set to pay out a little more than $1 billion to acquire digital pathology specialist Path AI in a mov…
May 8, 2026
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat
DealsFierceBiotech ↗
GSK pens $1B deal with China’s SiranBio for oligonucleotide that could reduce abdominal fat
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s hea…
May 7, 2026
Bayer Buys Perfuse for $2.4B, Targeting Next-Generation Eye Disease Therapy
DealsBriefing
Bayer Buys Perfuse for $2.4B, Targeting Next-Generation Eye Disease Therapy
The $300M upfront deal gives Bayer control of PER-001, a midphase implant for glaucoma and diabetic retinopath…
May 7, 2026